GSTM1 and cancer: Although different studies have shown that serial hemoglobin determinations have limited effectiveness as a diagnostic tool for early tumors, they have successfully identified a significant and a progressive decrease in Hb levels in CRC cases over a period of 3 to 4 years before diagnosis These findings reveal the potential of using such information to advance the subclinical detection of cancer and improve prognosis [62].